Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3645761 | 0.90 | MAOB (0.51) | CYP3A4MAOBMEN1KMT2AALOX5 | |
| SCHEMBL15063096 | 0.84 | CYP3A4 (0.49) | CYP3A4MAOBMEN1KMT2AMAPT | |
| SCHEMBL25552185 | 0.84 | CYP3A4 (0.51) | CYP3A4MAOBMEN1KMT2AALOX5 | |
| SCHEMBL5033238 | 0.84 | MAPT (0.54) | CYP3A4MAOBMEN1KMT2AMAPT | |
| SCHEMBL5033332 | 0.84 | MAOB (0.52) | CYP3A4MAOBMAPTACHERAB9A | |
| SCHEMBL28421218 | 0.82 | CYP3A4 (0.49) | CYP3A4MAOBMEN1KMT2AMAPT | |
| SCHEMBL2908224 | 0.82 | MCL1 (0.54) | CYP3A4MAOBMEN1KMT2AALOX5 | |
| SCHEMBL2907530 | 0.80 | MAOB (0.50) | CYP3A4MAOBMEN1KMT2AMAPT | |
| SCHEMBL27604099 | 0.79 | MEN1 (0.47) | CYP3A4MAOBMEN1KMT2AMAPT | |
| SCHEMBL30153587 | 0.79 | CYP3A4 (0.58) | CYP3A4MAOBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100376557-C | Quinoline derivatives as ligands for neuropeptide Y receptors | HOFFMANN LA ROCHE (CH) | 2008-03-26 | — | — | CN | disclosed |
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| CN-1522249-A | Quinoline derivatives as ligands for neuropeptide Y receptors | — | 2004-08-18 | — | — | CN | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | CYP3A4 3415/4885MAOB 1279/4885MEN1 1847/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | CYP3A4 3415/4885MAOB 1279/4885MEN1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.